Drug Trial Radar · NCT06287086
Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease
Last checked: Nov 19, 2026Latest source record: Jun 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1
Planned (sponsor's estimate)
Start
Jun 14, 2024
Primary completion
Aug 20, 2025
Study completion Jun 10, 2026
Sponsor
- Lead sponsor
- Bioray LaboratoriesIndustry
- Sponsor type
- Industry
- Collaborators
- Chinese Academy of Medical Sciences
- First posted
- Feb 29, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)
Conditions
- Sickle Cell Disease
Interventions
BRL-101 autologous hematopoietic stem and progenitor cells injectionDrug
CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of stem cell engrafted subjectsTime frame: Within 42 Days After BRL-101 Infusion
- Time to neutrophil engraftmentTime frame: Within 42 Days After BRL-101 Infusion
- Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusion..Time frame: Within 12 Months After BRL-101 Infusion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.